| TF Name |
Cell-line |
Condition/Source |
Collections |
Species |
Identifiers |
JASPAR ID |
| AR |
HEE (human epididymis epithelial cells) |
Treatment: without treatment of R1881 (methyltrienolone) |
Permissive
|
Homo sapiens |
GSE109061
...
|
MA0007.3
|
| AR |
HEE (human epididymis epithelial cells) |
Treatment: treatment of 1 nM R1881 (methyltrienolone) for 12 -16 hr |
Permissive
Robust
|
Homo sapiens |
GSE109061
...
|
MA0007.3
|
| AR |
A375 (malignant melanoma) |
Genotype: empty vector Tissue: skin Treatment: Cells were transfected with pcDNA3.1(-) empty vector control for 24 hr, post-seeding using Lipofectamine 2000 |
Permissive
|
Homo sapiens |
GSE116189
...
|
MA0007.3
|
| AR |
A375 (malignant melanoma) |
Genotype: empty vector Tissue: skin Treatment: Cells were transfected with pcDNA3.1(-) vector expressing SLNCR1 for 24 hr, post-seeding using Lipofectamine 2000 |
Permissive
|
Homo sapiens |
GSE116189
...
|
MA0007.3
|
| AR |
LNCaP-abl (Prostate carcinoma) |
Treatment: vehicle (DMSO) of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive |
Permissive
Robust
|
Homo sapiens |
GSE80238
...
|
MA0007.3
|
| AR |
LNCaP-abl (Prostate carcinoma) |
Treatment: EPZ-6438 of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive |
Permissive
|
Homo sapiens |
GSE80238
...
|
MA0007.3
|
| AR |
LNCaP-abl (Prostate carcinoma) |
Treatment: GSK126 of 5 uM for 4-5 days Passages: 61-64 Phenotype: AR-positive, EZH2 inhibitor -sensitive |
Permissive
Robust
|
Homo sapiens |
GSE80238
...
|
MA0007.3
|
| AR |
22RV1 (prostate carcinoma) |
Treatment: non-target siNT+R1881 |
Permissive
Robust
|
Homo sapiens |
GSE80742
...
|
MA0007.3
|
| AR |
22RV1 (prostate carcinoma) |
treatment: targeting ARV1/3/4/7 siARVs+R1881 |
Permissive
Robust
|
Homo sapiens |
GSE80742
...
|
MA0007.3
|
| AR |
22RV1 (prostate carcinoma) |
Treatment: targeting AR exon 7 siARFL+ ethanol |
Permissive
Robust
|
Homo sapiens |
GSE80742
...
|
MA0007.3
|
Showing 10 records in page 10
from 31 pages